T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
Cerus
CERS
$580M
| $1.21M | ﹤0.01% |
177,061
+68,117
| +63% | +$459K |
|
|
PINC
1927
DELISTED
Premier
PINC
| $1.21M | ﹤0.01% |
29,292
-1,025
| -3% | -$40.4K |
|
|
MZTI
1928
The Marzetti Company
MZTI
$3.18B
| $1.2M | ﹤0.01% |
7,252
-307
| -4% | -$50.3K |
|
1929
First Financial Bancorp
FFBC
$3.61B
| $1.2M | ﹤0.01% |
49,123
-3,405
| -6% | -$82.4K |
|
1930
Amkor Technology
AMKR
$14.4B
| $1.2M | ﹤0.01% |
48,238
-1,563
| -3% | -$36.4K |
|
1931
Primoris Services
PRIM
$4.44B
| $1.19M | ﹤0.01% |
49,637
+1,597
| +3% | +$40.4K |
|
1932
Kinsale Capital Group
KNSL
$8.67B
| $1.19M | ﹤0.01% |
4,987
-348
| -7% | -$68.5K |
|
|
ARI
1933
Apollo Commercial Real Estate
ARI
$887M
| $1.19M | ﹤0.01% |
90,037
-2,310
| -3% | -$33.4K |
|
1934
WisdomTree US MidCap Fund
EZM
$962M
| $1.19M | ﹤0.01% |
21,061
| – | – |
|
1935
GATX Corp
GATX
$6.36B
| $1.18M | ﹤0.01% |
11,353
-2,061
| -15% | -$205K |
|
1936
PMV Pharmaceuticals
PMVP
$66.1M
| $1.18M | ﹤0.01% |
51,224
-100,554
| -66% | -$2.43M |
|
|
VRE
1937
DELISTED
Veris Residential
VRE
| $1.18M | ﹤0.01% |
64,338
-1,489
| -2% | -$27.2K |
|
|
ESGR
1938
DELISTED
Enstar Group
ESGR
| $1.17M | ﹤0.01% |
4,741
-200
| -4% | -$47.5K |
|
|
EVBG
1939
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $1.17M | ﹤0.01% |
17,419
+1,590
| +10% | +$192K |
|
1940
First Hawaiian
FHB
$3.39B
| $1.17M | ﹤0.01% |
42,843
-2,244
| -5% | -$62.6K |
|
|
CIVI
1941
DELISTED
Civitas Resources
CIVI
| $1.17M | ﹤0.01% |
23,866
+4,751
| +25% | +$253K |
|
1942
RLI Corp
RLI
$5.85B
| $1.17M | ﹤0.01% |
20,840
-1,288
| -6% | -$69.7K |
|
1943
ImmunityBio
IBRX
$7.94B
| $1.16M | ﹤0.01% |
191,402
+9,300
| +5% | +$69.9K |
|
1944
International Bancshares
IBOC
$4.55B
| $1.16M | ﹤0.01% |
27,370
-1,868
| -6% | -$80.2K |
|
1945
Ligand Pharmaceuticals
LGND
$5.83B
| $1.16M | ﹤0.01% |
12,026
-1,994
| -14% | -$184K |
|
1946
Clear Channel Outdoor Holdings
CCO
$1.19B
| $1.16M | ﹤0.01% |
349,483
+139,261
| +66% | +$433K |
|
1947
Sphere Entertainment
SPHR
$6.24B
| $1.16M | ﹤0.01% |
16,431
-361,902
| -96% | -$25.4M |
|
1948
Beyond Meat
BYND
$7.09B
| $1.16M | ﹤0.01% |
591
-293
| -33% | -$748K |
|
1949
Antero Resources
AR
$11.4B
| $1.15M | ﹤0.01% |
65,841
-4,792
| -7% | -$90.8K |
|
|
B
1950
Barrick Mining
B
$67.8B
| $1.15M | ﹤0.01% |
60,462
-275
| -0.5% | -$5.22K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.